The stock of Guardant Health Inc. (NASDAQ:GH) last traded at $37.19, up 2.28% from the previous session.
Data from the available sources indicates that Guardant Health Inc. (NASDAQ:GH) is covered by 20 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $85.00 and a low of $30.00, we find $53.00. Given the previous closing price of $36.36, this indicates a potential upside of 45.76 percent. GH stock price is now 21.98% away from the 50-day moving average and 5.27% away from the 200-day moving average. The market capitalization of the company currently stands at $4.26B.
In total, 3 analysts have assigned it a hold rating, and 17 have given it a buy rating. Brokers who have rated the stock have averaged $54.00 as their price target over the next twelve months.
In other news, Joyce Meghan V., Director sold 2,766 shares of the company’s stock on Jun 15. The stock was sold for $103,863 at an average price of $37.55. Upon completion of the transaction, the Director now directly owns 4,224 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 09, Chief Information Officer Kalia Kumud bought 2,981 shares of the business’s stock. A total of $97,498 was incurred on buying the stock at an average price of $32.71. This leaves the insider owning 5,193 shares of the company worth $0.19 million. Insiders disposed of 43,258 shares of company stock worth roughly $1.61 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GH stock. A new stake in Guardant Health Inc. shares was purchased by JACOBS LEVY EQUITY MANAGEMENT, INC during the first quarter worth $32,149,000. NORGES BANK invested $29,270,000 in shares of GH during the first quarter. In the first quarter, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) acquired a new stake in Guardant Health Inc. valued at approximately $28,971,000. D. E. SHAW & CO., INC. acquired a new stake in GH for approximately $18,248,000. SQUAREPOINT OPS LLC purchased a new stake in GH valued at around $9,671,000 in the second quarter. In total, there are 421 active investors with 94.00% ownership of the company’s stock.
With an opening price of $36.34 on Friday morning, Guardant Health Inc. (NASDAQ: GH) set off the trading day. During the past 12 months, Guardant Health Inc. has had a low of $20.67 and a high of $62.75. The fifty day moving average price for GH is $30.80 and a two-hundred day moving average price translates $35.24 for the stock.
The latest earnings results from Guardant Health Inc. (NASDAQ: GH) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$1.3, beating analysts’ expectations of -$1.31 by 0.01. This compares to -$1.21 EPS in the same period last year. The company reported revenue of $128.71 million for the quarter, compared to $96.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 33.94 percent. For the current quarter, analysts expect GH to generate $129.41M in revenue.
Guardant Health Inc.(GH) Company Profile
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
